Janus Henderson Group PLC Reata Pharmaceuticals Inc Transaction History

Janus Henderson Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $65.6 Million - $87.2 Million	827,758 Added 370.66%	1,051,077 $107 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $6.72 Million - $20.3 Million	217,947 Added 4057.09%	223,319 $20.3 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $118,989 - $226,214	5,372 New	5,372 $204,000
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $5.63 Million - $10.9 Million	-71,876 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $2.1 Million - $2.96 Million	22,285 Added 44.94%	71,876 $7.17 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $5.06 Million - $9.16 Million	49,591 New	49,591 $6.13 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.